Research programme: chemokine therapeutics - Biokine

Drug Profile

Research programme: chemokine therapeutics - Biokine

Alternative Names: BKT 130; BKT-RP3

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Biokine Therapeutics
  • Class
  • Mechanism of Action Chemokine modulators; Chemokine receptor agonists; Chemokine receptor antagonists; Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Rheumatoid arthritis
  • Discontinued Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 29 Jan 2016 BKT 130 is still in preclinical development for Rheumatoid Arthritis and Multiple Sclerosis in Israel (Biokine pipeline, January 2016)
  • 11 Jul 2011 Preclinical trials in Rheumatoid arthritis in Israel (IV)
  • 11 Jul 2011 Preclinical trials in Multiple sclerosis in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top